FOLH1 and cancer: The widespread expression of ofCS in cancers and the efficient targeting potential of rVAR2 offers additional advantages over bispecific molecules targeting tumor-specific antigens such as CEA, CD20, or PSMA, which are restricted to a much narrower range of cancers67,68.